Fortress Biotech Inc (FBIO)
1.61
-0.04
(-2.42%)
USD |
NASDAQ |
Nov 14, 10:47
Fortress Biotech Revenue (Quarterly): 14.90M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 14.90M |
| March 31, 2024 | 13.03M |
| December 31, 2023 | 19.95M |
| September 30, 2023 | 34.75M |
| June 30, 2023 | 17.39M |
| March 31, 2023 | 12.43M |
| December 31, 2022 | 16.40M |
| September 30, 2022 | 16.53M |
| June 30, 2022 | 18.89M |
| March 31, 2022 | 23.92M |
| December 31, 2021 | 18.28M |
| September 30, 2021 | 21.08M |
| June 30, 2021 | 17.84M |
| March 31, 2021 | 11.59M |
| December 31, 2020 | 13.75M |
| September 30, 2020 | 9.475M |
| June 30, 2020 | 9.457M |
| March 31, 2020 | 12.92M |
| December 31, 2019 | 11.13M |
| Date | Value |
|---|---|
| September 30, 2019 | 9.772M |
| June 30, 2019 | 9.25M |
| March 31, 2019 | 6.477M |
| December 31, 2018 | 8.991M |
| September 30, 2018 | 5.173M |
| June 30, 2018 | 6.815M |
| March 31, 2018 | 5.903M |
| December 31, 2017 | -125.02M |
| September 30, 2017 | 46.89M |
| June 30, 2017 | 50.70M |
| March 31, 2017 | 44.68M |
| December 31, 2016 | 12.62M |
| September 30, 2016 | 0.975M |
| June 30, 2016 | 2.23M |
| March 31, 2016 | 0.66M |
| December 31, 2015 | 0.338M |
| September 30, 2015 | 0.025M |
| June 30, 2015 | |
| March 31, 2015 | 0.50M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
9.457M
Minimum
Jun 2020
34.75M
Maximum
Sep 2023
16.51M
Average
16.40M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| Journey Medical Corp | 14.86M |
| Checkpoint Therapeutics Inc | 0.041M |
| Avenue Therapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.95M |
| Total Expenses (Quarterly) | 40.04M |
| EPS Diluted (Quarterly) | -10.95 |
| Enterprise Value | -1.023M |
| Gross Profit Margin (Quarterly) | 56.09% |
| Profit Margin (Quarterly) | -73.50% |
| Earnings Yield | -835.2% |
| Normalized Earnings Yield | -717.01 |